v3.25.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Operating expenses:        
Research and development $ 208,021 $ 30,798 $ 259,286 $ 61,671
Acquired in-process research and development expense 0 15,007 0 15,007
General and administrative 360,416 13,812 376,002 25,328
Total operating expenses 568,437 59,617 635,288 102,006
Other income, net 2,729 2,334 6,667 4,371
Interest expense 0 (3,102) 0 (6,223)
Net loss $ (565,708) $ (60,385) $ (628,621) $ (103,858)
Net loss per share:        
Basic (in dollars per share) $ (0.76) $ (0.09) $ (0.85) $ (0.15)
Diluted (in dollars per share) $ (0.76) $ (0.09) $ (0.85) $ (0.15)
Weighted average common shares outstanding:        
Basic (in shares) 742,615,007 707,904,643 740,358,044 704,844,946
Diluted (in shares) 742,615,007 707,904,643 740,358,044 704,844,946
Other comprehensive loss:        
Foreign currency translation adjustments $ (189) $ 92 $ (334) $ 82
Reclassification of unrealized loss on short-term investments to other expense, net 0 3 0 3
Unrealized loss on short-term investments 0 (45) (133) (34)
Comprehensive loss $ (565,897) $ (60,335) $ (629,088) $ (103,807)